TELO logo

TELOMIR PHARMACEUTICALS INC

TELONASDAQ
๐Ÿ† #3663 by market capEarnings Sep 2US Equity
$1.11โ–ผ $0.02 (โˆ’2.21%)
Live
1hโ€”
24hโ–ผ 2.2%
7dโ–ผ 3.9%
14dโ–ผ 7.9%
30dโ–ผ 9.8%
1yโ–ผ 29.6%
๐ŸฆMarket Cap
$76M
Small Cap
๐Ÿ“ˆRevenue Growth (YoY)
+0.0%
Slowing
๐Ÿ“ŠGross Margin
0.0%
Thin
๐Ÿ’ตFCF Margin
0.0%
Thin
โš–๏ธP/S Ratio
0.0x
Cheap
Otter Score
63
Fair

Trading Snapshot

Day Range
$1.10 โ€“ $1.11
52-Week Range
$0.89 โ€“ $2.09
Volume
$3.84B
Avg Volume
$2.68B
Shares Outstanding
68.8M
Next Earnings
Sep 10, 2026

Fundamentals Snapshot

Annual Revenue
$8M
Last Q Revenue
$2M
P/E Ratio
-3.8
P/S Ratio
0.0x
EPS (TTM)
$-0.27
Dividend Yield
0.00%

Why Investors Own TELO

  • โœ“High-growth profile โ€” revenue up +25.5% YoY with expanding US Equity exposure.
  • โœ“Healthy economics โ€” 73% gross margin and 29% free-cash-flow margin.
  • โœ“New products and segments could unlock additional revenue streams.
โš ๏ธ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)
$8Mโ–ฒ +22.8% YoY
Gross Margin (TTM)
72.7%โ–ฒ +3.8% YoY
Operating Income (TTM)
$2Mโ–ฒ +22.8% YoY
Free Cash Flow (TTM)
$2Mโ–ฒ +22.8% YoY

About TELOMIR PHARMACEUTICALS INC

Telomir Pharmaceuticals, Inc. operates as a preclinical-stage pharmaceutical firm, concentrating its efforts on creating and launching novel therapeutic interventions. Its primary focus involves the development of TELOMIR-1, an innovative small molecule compound. This oral medication is being engineered to serve as a therapeutic solution against various age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, and also to assist in recovery post-chemotherapy. It achieves this by disrupting and inhibiting inflammatory pathways that are triggered by interleukin-17. Established in 2021, the company was initially known as Metallo Therapies Inc., officially adopting the name Telomir Pharmaceuticals, Inc. on October 10, 2022. The company's headquarters are located in Baltimore, Maryland.

๐Ÿฆฆ

Otter Score Breakdown

โ“˜
๐Ÿ’ŽQualityโ˜…โ˜…โ˜…โ˜…โ˜…
๐Ÿš€Growthโ˜…โ˜…โ˜…โ˜…โ˜…
โš–๏ธValuationโ˜…โ˜…โ˜…โ˜…โ˜…
โšกMomentumโ˜…โ˜…โ˜…โ˜…โ˜…
Overall Score
Fair
63/100

Analyst Price Target

โ“˜
Average Target
$1.19
โ–ฒ +8.0% Upside
High Target$1.47
Low Target$1.11
Based on 41 analysts

Latest News & Updates